https://pharmadevicenews.com/zipalertinib-controlled-brain-disease-in-72-of-patients-could-it-address-a-major-egfr-treatment-gap/ PharmaDeviceNews en 2026-10-20T05:02:37+00:00 Zipalertinib controlled brain disease in 72% of patients. Could it address a major EGFR treatment gap? brain metastases, CLN-081, Cullinan Therapeutics, EGFR exon 20 insertion, ESMO 2026, FDA, Helena Yu, Leptomeningeal Disease, Memorial Sloan Kettering Cancer Center, non-small cell lung cancer, Otsuka Holdings, REZILIENT2, REZILIENT3, Taiho Oncology, Taiho Pharmaceutical, TAS6417, Zipalertinib https://pharmadevicenews.com/wp-content/uploads/2026/08/Lung-cancer-study-e1787082418957.webp https://pharmadevicenews.com/frontier-to-reveal-first-fmc-376-clinical-responses-in-kras-g12c-lung-cancer/ PharmaDeviceNews en 2026-10-20T04:58:19+00:00 Frontier to reveal first FMC-376 clinical responses in KRAS G12C lung cancer Adagrasib, Chemoproteomics, Covalent Inhibitors, ESMO 2026, FMC-376, Frontier Medicines, KRAS G12C, KRAS Inhibitor Resistance, Marcelo Negrao, MD Anderson Cancer Center, non-small cell lung cancer, pembrolizumab, precision oncology, PROSPER, sotorasib https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-17-2026-09_15_56-AM-e1789616803290.webp https://pharmadevicenews.com/zap-surgical-secures-36m-to-expand-zap-x-brain-radiosurgery/ PharmaDeviceNews en 2026-10-20T04:54:32+00:00 ZAP Surgical secures $36m to expand ZAP-X brain radiosurgery Baheal, Brain Tumors, Catalio Capital Management, FDA, Gyroscopic Radiosurgery, John Adler, Medical Linear Accelerators, neuro-oncology, radiation oncology, Radiomodulation, Stanford University, Stereotactic Radiosurgery, treatment-resistant depression, ZAP Surgical Systems, ZAP-X https://pharmadevicenews.com/wp-content/uploads/2026/10/ZAP-Surgical-expands-brain-radiosurgery-beyond-major-academic-hospitals-e1792472030263.webp https://pharmadevicenews.com/faeth-to-present-piktor-breast-cancer-data-comparing-multi-node-cancer-treatments/ PharmaDeviceNews en 2026-10-20T04:13:40+00:00 Faeth to present PIKTOR breast cancer data comparing multi-node cancer treatments AKT, Anand Parikh, Celcuity, ESMO 2026, Faeth Therapeutics, FTH-PIK-101, FTH-PIK-201, fulvestrant, Gedatolisib, HER2-negative breast cancer, hormone receptor-positive breast cancer, mTOR, Oliver Maddocks, PI3K, PIKTOR, sapanisertib, serabelisib https://pharmadevicenews.com/wp-content/uploads/2026/05/Menarinis-ELEVATE-data-show-why-mutation-driven-breast-cancer-combinations-are-gaining-attention-e1779988908164.webp https://pharmadevicenews.com/gileads-herpes-candidate-cut-viral-shedding-by-98-what-will-its-latest-idweek-data-reveal/ PharmaDeviceNews en 2026-10-20T04:09:44+00:00 Gilead’s herpes candidate cut viral shedding by 98%. What will its latest IDWeek data reveal? ACCELERATE, ARTISTRY-1, ARTISTRY-2, Assembly Biosciences, Bictegravir, BIKTARVY, Bixlenvo, Gilead Sciences, GS-1179, herpes simplex virus, IDWeek 2026, Lenacapavir, PURPOSE 1, PURPOSE 2, PURPOSE 4, Yeztugo https://pharmadevicenews.com/wp-content/uploads/2026/06/Gilead-and-Merck-gain-HIV-momentum-but-face-fresh-oncology-questions.-See-why-this-split-pipeline-update-matters-e1780976857519.webp https://pharmadevicenews.com/merck-is-paying-a-130-premium-for-silence-therapeutics-is-divesiran-the-main-prize/ PharmaDeviceNews en 2026-10-20T04:02:35+00:00 Merck is paying a 130% premium for Silence Therapeutics. Is divesiran the main prize? divesiran, Hepcidin, Iain Ross, Kai Beckmann, lipoprotein(a), Merck KGaA, Mergers and Acquisitions, mRNAi GOLD, polycythemia vera, RNA interference, SANRECO, Silence Therapeutics, SpringWorks Therapeutics, TMPRSS6, Zerlasiran https://pharmadevicenews.com/wp-content/uploads/2026/08/Silence-Therapeutics-strengthens-cash-position-as-divesiran-advances-in-polycythemia-vera-e1786508171750.webp https://pharmadevicenews.com/ge-healthcares-new-ultrasound-system-is-26-faster-in-testing-can-it-reduce-imaging-bottlenecks/ PharmaDeviceNews en 2026-10-19T14:29:43+00:00 GE HealthCare’s new ultrasound system is 26% faster in testing. Can it reduce imaging bottlenecks? artificial intelligence, Auto Preset Assistant, AutoEF, cSound Architecture, FDA, GE HealthCare, Liver Elastography, LOGIQ, LOGIQ Focus, medical imaging, SonoDefense, ultrasound imaging, Ultrasound-Guided Fat Fraction, Verisound Collab, Vscan Air https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Scan-imaging-generic.webp https://pharmadevicenews.com/sound-pharma-reports-phase-3-hearing-gains-with-spi-1005-targeting-sudden-hearing-loss/ PharmaDeviceNews en 2026-10-19T14:23:40+00:00 Sound Pharma reports Phase 3 hearing gains with SPI-1005, targeting sudden hearing loss AAO-HNS 2026, American Academy of Otolaryngology Head and Neck Surgery, Breakthrough Therapy designation, Ebselen, FDA, Glutathione Peroxidase, Jonathan Kil, Ménière's Disease, Pure-Tone Audiometry, Sound Pharmaceuticals, SPI-1005, STOPMD-3, sudden sensorineural hearing loss, Words-in-Noise Test https://pharmadevicenews.com/wp-content/uploads/2026/06/Acousia-Therapeutics-moves-bimokalner-from-otoprotection-hypothesis-to-clinical-proof-question-e1781273977573.webp https://pharmadevicenews.com/pharmaessentia-reports-55-two-year-besremi-persistence-in-polycythemia-vera/ PharmaDeviceNews en 2026-10-19T14:20:07+00:00 PharmaEssentia reports 55% two-year BESREMi persistence in polycythemia vera Anagrelide, BESREMi, essential thrombocythemia, EXCEED ET, FDA, Hydroxyurea, International Congress on Myeloproliferative Neoplasms, JAK2 V617F, myeloproliferative neoplasms, PharmaEssentia, polycythemia vera, ropeginterferon alfa-2b, SURPASS ET https://pharmadevicenews.com/wp-content/uploads/2026/06/Venclextas-nine-year-CLL-data-reinforce-AbbVies-role-in-blood-cancer-therapy-e1781257107485.webp https://pharmadevicenews.com/vivacta-and-grit-bio-advance-cd19-targeting-car-t-without-external-cell-manufacturing/ PharmaDeviceNews en 2026-10-18T16:58:48+00:00 Vivacta and Grit Bio advance CD19-targeting CAR-T without external cell manufacturing American Society of Gene and Cell Therapy, Autoimmune Hemolytic Anemia, B-cell depletion, CD19, cell therapy, CLAMP Technology, FDA, Grit Biotherapeutics, GT801, in vivo CAR-T, lipid nanoparticles, Messenger RNA, orphan drug designation, Vivacta Bio, Yarong Liu https://pharmadevicenews.com/wp-content/uploads/2026/06/Johnson-Johnson-strengthens-nipocalimabs-FDA-case-with-rapid-hemoglobin-improvement-e1781938581377.webp https://pharmadevicenews.com/can-a-pulse-oximeter-detect-atrial-fibrillation-before-symptoms-appear-masimo-reports-97-sensitivity/ PharmaDeviceNews en 2026-10-18T16:55:11+00:00 Can a pulse oximeter detect atrial fibrillation before symptoms appear? Masimo reports 97% sensitivity artificial intelligence, atrial fibrillation, Danaher, Electrocardiography, FDA, Hospital Patient Safety, Masimo, Masimo SET, Opioid-Induced Respiratory Depression, patient monitoring, photoplethysmography, Pulse Oximetry, Radius VSM, smartSET https://pharmadevicenews.com/wp-content/uploads/2026/10/Masimo-smartSET-receives-FDA-clearance-for-atrial-fibrillation-detection-e1792342473285.webp https://pharmadevicenews.com/ionis-tryngolza-wins-eu-recommendation-after-85-reduction-in-pancreatitis-events/ PharmaDeviceNews en 2026-10-18T16:50:29+00:00 Ionis TRYNGOLZA wins EU recommendation after 85% reduction in pancreatitis events acute pancreatitis, apolipoprotein C-III, CHMP, CORE, CORE2, European Commission, European Medicines Agency, familial chylomicronemia syndrome, Ionis Pharmaceuticals, olezarsen, severe hypertriglyceridemia, Sobi, TIMI Study Group, Tryngolza https://pharmadevicenews.com/wp-content/uploads/2026/06/Ionis-Pharmaceuticals-wins-FDA-approval-for-Tryngolza-in-severe-hypertriglyceridemia-e1782660918624.webp https://pharmadevicenews.com/estuary-launches-with-103m-to-develop-gene-therapies-for-polycystic-kidney-disease/ PharmaDeviceNews en 2026-10-18T05:59:09+00:00 Estuary launches with $103m to develop gene therapies for polycystic kidney disease 4BIO Capital, autosomal dominant polycystic kidney disease, Biogen New Ventures, Deep Track Capital, EST-101, EST-201, Estuary Biotherapeutics, gene therapy, GV, Michael Caplan, National Kidney Foundation Innovation Fund, PKD1, PKD2, RA Capital Management, Stefan Somlo, UPMC Enterprises, Wayne Sackett, Yale School of Medicine https://pharmadevicenews.com/wp-content/uploads/2026/02/Arcus-Biosciences-casdatifan-data-test-whether-next-generation-HIF-2α-inhibition-can-outperform-late-line-kidney-cancer-expectations-e1771916981796.webp https://pharmadevicenews.com/omeros-faces-second-european-rejection-for-yartemlea-despite-us-approval/ PharmaDeviceNews en 2026-10-18T05:55:32+00:00 Omeros faces second European rejection for YARTEMLEA despite US approval CHMP, complement inhibition, European Medicines Agency, FDA, Gregory Demopulos, Hematopoietic Stem Cell Transplantation, MASP-2, narsoplimab, Omeros Corporation, OMS1029, Transplant-Associated Thrombotic Microangiopathy, YARTEMLEA https://pharmadevicenews.com/wp-content/uploads/2026/01/transplant‑associated-thrombotic-microangiopathy.webp https://pharmadevicenews.com/fda-approves-genentechs-enspryng-as-first-at-home-treatment-for-thyroid-eye-disease/ PharmaDeviceNews en 2026-10-18T05:40:08+00:00 FDA approves Genentech’s ENSPRYNG as first at-home treatment for thyroid eye disease autoimmune diseases, Chugai Pharmaceutical, Enspryng, FDA, Genentech, Graves Ophthalmopathy, Interleukin-6 Receptor, ophthalmology, Roche, SatraGO-1, SatraGO-2, satralizumab, Tepezza, thyroid eye disease https://pharmadevicenews.com/wp-content/uploads/2026/06/Viridian-launches-Lumvoa-after-FDA-approval-opening-first-direct-challenge-to-Tepezza-e1782532224938.webp